Danah Al Shaer, Othman Al Musaimi, Fernando Albericio, and Beatriz G. de la Torre
Pharmaceuticals, Vol 12, Iss 2, p 52 (2019)
dotatate, drugs, inotersen, Lutathera, oligonucleotides, Onpattro, patisiran, peptides, pharmaceutical market, Tegsedi, Pharmacy and materia medica, and RS1-441
In 2018, the United States Food and Drug Administration (FDA) approved a total of 59 new drugs, three of them (5%) are TIDES (or also, -tides), two oligonucleotides and one peptide. Herein, the three TIDES approved are analyzed in terms of medical target, mode of action, chemical structure, and economics.
Othman Al Musaimi, Danah Al Shaer, Beatriz G. de la Torre, and Fernando Albericio
Pharmaceuticals, Vol 11, Iss 2, p 42 (2018)
pharmaceutical market, drugs, drug discovery, solid-phase peptide synthesis, Pharmacy and materia medica, and RS1-441
2017 was an excellent year in terms of new drugs (chemical entities and biologics) approved by the FDA, with a total of 46. In turn, one of the highlights was the number of peptides (six) included in this list. Here, the six peptides are analyzed in terms of chemical structure, synthetic strategy used for their production, source, therapeutic use, and mode of action.